Etanercept and infections;Etanercept e infecciones

Actas Dermo-Sifiliograficas

Volumn 101, Issue SUPPL. 1, 2010, Pages 70-76

  Ribera, M ^a   Leal, L ^a   Luelmo, J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Conjunctivitis; Etanercept; Infection; Pityriasis versicolor; Skin infections

Indexed keywords

CICLOPIROXOLAMINE; CYCLOSPORIN A; DEXAMETHASONE; EFALIZUMAB; ETANERCEPT; KETOCONAZOLE; METHOTREXATE; TOBRAMYCIN; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTHRITIS; ARTICLE; CASE REPORT; CLINICAL EVALUATION; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMODIALYSIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INTRAVENOUS CATHETER; LIVER TOXICITY; MALE; PSORIASIS; PSORIASIS SEVERITY INDEX; SEPSIS; URINARY CATHETER; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CONJUNCTIVITIS; MIDDLE AGED; TINEA VERSICOLOR;

ADULT; CONJUNCTIVITIS, BACTERIAL; HUMANS; IMMUNOGLOBULIN G; INFECTION; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TINEA VERSICOLOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952514411     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S0001-7310(10)70012-0     Document Type: Article

References (73)

1. L. Puig, J.M. Carrascosa, E. Daudén, J.L. Sánchez-Carazo, C. Ferrándiz, and M. Sánchez-Regaña Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos Actas Dermosifiliogr 100 2009 386 413
2. M. Bakleh, I. Tleyjeh, E.L. Matteson, D.R. Osmon, and E.F. Berbari Infectious complications of tumor necrosis factor-alpha antagonists Int J Dermatol 44 2005 443 448
3. J.M. García-Lechuz Moya Complicaciones infecciosas asociadas al uso de medicamentos antiTNF: revisión Enferm Infecc Microbiol Clin 23 2005 551 559
4. M.P. Galindo, B.L. Bartlett, A. Gewirtzman, N. Mendoza, A.M. Tremaine, and S.K. Tyring Etanercept: an overview of its role in the treatment of psoriasis Expert Opin Drug Metab Toxicol 4 2008 305 310
5. A.E. Moustou, A. Matekovits, C. Dessinioti, C. Antoniou, P.P. Sfikakis, and A.J. Stratigos Cutaneous side effects of anti-tumor necrosis factor biologic therapy: A clinical review J Am Acad Dermatol 61 2009 486 504
6. V. Crespo Generalidades sobre los hongos. Dermatomicosis: saproficias y dermatofitosis Piel 23 2008 389 396
7. V. Crespo ¿Quién es el responsable de la pitiriasis versicolor? Piel 17 2002 147 149
8. M.S. Levy, D. Polsky, A. Davidson, and B.E. Strober Tinea versicolor associated with etanercept therapy J Am Acad Dermatol 58 5 Suppl 1 2008 S99 S100
9. M. Hannuksela Cutaneous rash from the use of medicine for rheumatoid arthritis Duodecim 122 2006 105 111
10. R.C. Arffa Diseases of the skin. Grayson's Diseases of the Cornea 3rd ed. 1991 Mosby St Louis p. 539-42
11. S. Iijima, M. Iwata, and F. Otsuka Psoriatic arthritis and hypopyon-iridocyclitis. Possible mechanism of the association of psoriasis and anterior uveitis Dermatology 193 1996 295 299
12. Y. Yamamato, R. Tada, Y. Shimomura, and T. Yuasa A case of recurrent hypopyon uveitis with psoriasis pustulosa Jpn J Clin Ophthalmol 36 1982 217 221
13. G. Wagner, J.R. Luckasen, and R.W. Goltz Mucous membrane involvement in generalized pustular psoriasis: report of three cases and review of the literature Arch Dermatol 112 1976 1010 1014
14. A. Catsarou-Catsari, A. Katsambas, P. Theodoropoulos, and J. Stratigos Ophthalmological manifestations in patients with psoriasis Acta Derm Venereol 64 1984 557 559
15. A.A. Karabulut, I.S. Yalvac, H. Vahaboglu, A.B. Nurozler, and S. Duman Conjunctival impression cytology and tear-film changes in patients with psoriasis Cornea 18 1999 544 548
16. N. Zengin, H. Tol, S. Balevi, K. Gunduz, S. Okudan, and H. Endogru Tear film and meibomian gland functions in psoriasis Acta Ophthalmol Scand 74 1996 358 360
17. D.L. Knox Psoriasis and intraocular inflammation Trans Am Ophthalmol Soc 77 1979 210 224
18. F. Okamoto, T. Sato, Y. Umebayashi, F. Ohtsuka, and S. Hommura Quantitative evaluation of aqueous flare in psoriasis using a laser flare-cell meter Nippon Ganka Gakkai Zasshi 101 1997 487 491
19. K.r. Moadel, H.D. Perry, E.D. Donnenfeld, B. Zagelbaum, and H.J. Ingraham Psoriatic corneal abscess Am J Ophthalmol 119 1995 800 801
20. J.E. Thorne, N.J. Volpe, and G.T. Liu Magnetic resonance imaging of acquired Brown syndrome in a patient with psoriasis Am J Ophthalmol 127 1999 233 235
21. R. Ajitsaria, R. Dale, V. Ferguson, S. Mayou, and N. Cavanagh Psoriasis, psoriatic arthropathy and relapsing orbital myositis Clin Exp Dermatol 26 2001 274 275
22. I. Erbagci, Z. Erbagci, K. Gungor, and N. Bekir Ocular anterior segment pathologies and tear film changes in patients with psoriasis vulgaris Acta Med Okayama 57 2003 299 303
23. L.H. Kircik, and J.Q. Del Rosso Anti-TNF agents for the treatment of psoriasis J Drugs Dermatol 8 2009 546 559
24. J.M. Shehan, and D.P. Sarma Mycobacterium mucogenicum: report of a skin infection associated with etanercept Dermatol Online J 14 2008 5
25. N. Maimon, J. Brunton, A.K. Chan, and T.K. Marras Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept Thorax 62 2007 739 740
26. J. Van Ingen, M. Boeree, M. Janssen, E. Ullmann, W. de Lange, and P. de Haas Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy Nat Clin Pract Rheumatol 3 2007 414 419
27. A.H. Mufti, B.W. Toye, R.R. Mckendry, and J.B. Angel Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use Diagn Microbiol Infect Dis 53 2005 233 238
28. J.E. Thomas, C.R. Taoka, B.T. Gibbs, and S.L. Fraser Fatal pulmonary Mycobacterium abscessus infection in a patient using etanercept Hawaii Med J 65 2006 12 15
29. K. Ndarajah, and C. Pritchard Listeria monocytogenes septic arthritis in a patient treated with etanercept for rheumatoid arthritis J Clin Rheumatol 11 2005 120 122
30. S. Rachapalli, and S. O'Daunt Septic arthritis due to Listeria monocytogenes in a patient receiving etanercept Arthritis Rheum 52 2005 987
31. G. Schett, P. Herak, W. Graninger, J.S. Smolen, and M. Aringer Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature J Clin Microbiol 43 2005 2537 2541
32. Al-Tawfiq JA, Al-Khatti AA. Disseminated systemic Nocardia farcinica infection complicating alefacept and infliximab therapy in a patient with severe psoriasis. Int J Infect Dis. 2009 (en prensa).
33. P. Arriola-Villalobos, D. Díaz-Valle, N. Alejandre-Alba, C. López-Abad, R. Méndez-Fernández, and J.M. Benítez-del-Castillo Bilateral Candida chorioretinitis following etanercept treatment for hidradenitis suppurativa Eye 22 2008 599 600
34. J.K. Hoang, and J. Burruss Localized cutaneous Cryptococcus albidus infection in a 14-year-old boy on etanercept therapy Pediatr Dermatol 24 2007 285 288
35. J. Bourre-Tessier, C. Fortin, A. Belisle, E. Desmarais, D. Choquette, and J.L. Senecal Disseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept Scand J Rheumatol 14 2009 1 6
36. S. Tsiodras, G. Samonis, D.T. Boumpas, and D.P. Kontoyiannis Fungal infections complicating tumor necrosis factor alpha blockade therapy Mayo Clin Proc 83 2008 181 194
37. E. Calabuig, and M. Salavert Riesgo infeccioso Actas Dermosifiliogr 99 Supl 4 2008 14 22
38. J.C. Lagier, D. Andriamanantena, J. Damiano, J.M. Dot, B. Chaudier, and J. Margery Anti-TNF alpha therapy: a risk factor for legionella infection Rev Mal Respir 24 2007 1159 1160
39. F. Tubach, P. Ravaud, D. Salmon-Céron, N. Petitpain, O. Brocq, and F. Grados Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists Clin Infect Dis 43 2006 e95 e100
40. I. Uthman, A. Husari, Z. Touma, and S.S. Kanj Fatal streptococcal toxic shock syndrome in a patient with rheumatoid artritis treated with etanercept Rheumatology (Oxford) 44 2005 1200 1201
41. Y. Waguri-Nagaya, M. Kobayashi, H. Goto, S. Hisazaki, A. Tsuchiya, and T. Otsuka Septic arthritis of the right ankle caused by Staphylococcus aureus infection in a rheumatoid arthritis patient treated with etanercept Mod Rheumatol 17 2007 338 340
42. S. Bassetti, S. Wasmer, P. Hasler, T. Vogt, D. Nogarth, and R. Frei Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment J Rheumatol 32 2005 2125 2129
43. C. Núñez-Cornejo, J. Borrás-Blasco, A. Gracia-Pérez, J.D. Rosique-Robles, V. López-Camps, and E. Castera Septic shock and community- acquired pneumonia associated with etanercept therapy Int J Clin Pharmacol Ther 46 2008 193 197
44. J. Borrás-Blasco, C. Núñez-Cornejo, A. Gracia-Pérez, J.D. Rosique- Robles, M.D. Casterá, and E. Viosca Parapharyngeal abscess in a patient receiving etanercept Ann Pharmacother 41 2007 341 344
45. D.D. Sweet, G. Isac, B. Morrison, J. Fenwick, and V. Dhingra Purulent pericarditis in a patient with rheumatoid arthritis treated with etanercept and methotrexate CJEM 9 2007 40 42
46. A. Mor, H.J. Mitnick, J.B. Greene, N. Azar, R. Budnah, and J. Fetto Relapsing oligoarticular septic arthritis during etanercept treatment of rheumatoid arthritis J Clin Rheumatol 12 2006 87 89
47. B. Killingley, V. Carpenter, K. Flanagan, and G. Pasvol Pneumococcal meningitis and etanercept- chance or association? J Infect 51 2005 49 51
48. B. Petersen, and H. Lorentzen Cytomegalovirus complicating biological immunosuppressive therapy in two patients with psoriasis receiving treatment with etanercept or efalizumab Acta Derm Venereol 88 2008 523 524
49. E.A. Justice, S.Y. Khan, S. Logan, and P. Jobanputra Disseminated cutaneous Herpes Simplex Virus-1 in a woman with rheumatoid arthritis receiving Infliximab: A case report J Med Case Reports 2 2008 282
50. Tresch S, Trüeb RM, Kamarachev J, French LE, Hofbauer GF. Disseminated Herpes Zoster mimicking rheumatoid vasculitis in a rheumatoid arthritis patient on Etanercept. Dermatology. 2009 (en prensa).
51. A. Strangfeld, J. Listing, P. Herzer, A. Liebhaber, K. Rockwitz, and C. Richter Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents JAMA 301 2009 737 744
52. C. Cursiefen, M. Grunke, C. Dechant, C. Antoni, A. Junemann, and L.M. Holbach Multiple bilateral eyelid Molluscum contagiosum lesions associated with TNFalpha-antibody and methotrexate therapy Am J Ophthalmol 134 2002 270 271
53. C. Antoniou, M.G. Kosmadaki, A.J. Stratigos, and A.D. Katsambas Genital HPV lesions and Molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy Dermatology 216 2008 364 365
54. L. Leal, M. Ribera, and E. Daudén Psoriasis e infección por el virus de la inmunodeficiencia humana Actas Dermosifiliogr 99 2008 753 763
55. S. Domm, J. Cinatl, and U. Mrowietz The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature Br J Dermatol 159 2008 1217 1228
56. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2008 (en prensa).
57. E. Toussirot, G. Streit, and D. Wendling Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review Recent Pat Inflamm Allergy Drug Discov 1 2007 39 47
58. K. Darabi, R. Jaiswal, S. Hostetler, M. Bechtel, and M. Zirwas Infectious complications in patients with psoriasis and rheumatoid arthritis treated with antitumor necrosis factor agents and methotrexate J Drugs Dermatol 8 2009 175 178
59. C. Salliot, L. Gossec, A. Ruyssen-Witrand, M. Luc, M. Duclos, and S. Guignard Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients Rheumatology (Oxford) 46 2007 327 334
60. E.G. Favalli, F. Desiati, F. Atzeni, P. Sarzi-Puttini, R. Caporali, and F.B. Pallavicini Serious infections during anti-TNFalpha treatment in rheumatoid artritis patients Autoimmun Rev 8 2009 266 273
61. M.F. Doran, C.S. Crowson, G.R. Pond, W.M. O'Fallon, and S.E. Gabriel Frequency of infection in patients with rheumatoid artritis compared with controls: a population-based study Artritis Rheum 46 2002 2287 2293
62. P.L. van Riel, A.J. Taggart, J. Sany, M. Gaubitz, H.W. Nab, and R. Pedersen Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study Ann Rheum Dis 65 2006 1478 1483
63. L. Klareskog, D. van der Heijde, J.P. de Jager, A. Gough, J. Kalden, and M. Malaise Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 2004 675 681
64. P. Emery, F.C. Breedveld, S. Hall, P. Durez, D.J. Chang, and D. Robertson Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid artritis (COMET): a randomised, double-blind, parallel treatment trial Lancet 372 2008 375 382
65. L.W. Moreland, M.E. Weinblatt, E.C. Keystone, J.M. Kremer, R.W. Martin, and M.H. Schiff Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience J Rheumatol 33 2006 854 861
66. M. Ribera Etanercept en psoriasis 2008 Farmacia Comunicación S.L. Barcelona
67. J.L. Sánchez, L. Mahiques, and V. Oliver Safety of etanercept in psoriasis: a critical review Drug Saf 29 2006 675 685
68. K.A. Papp The safety of etanercept for the treatment of plaque psoriasis Ther Clin Risk Manag 3 2007 245 258
69. A.B. Gottlieb, C.L. Leonardi, B.S. Goffe, J.P. Ortonne, P.C. van der Kerkhof, and R. Zitnik Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database J Am Acad Dermatol 54 Suppl 2006 S92 S100
70. S. Tyring, K.B. Gordon, Y. Poulin, R.G. Langley, A.B. Gottlieb, and M. Dunn Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 143 2007 719 726
71. J. Listing, A. Strangfeld, S. Kary, R. Rau, U. von Hinueber, and M. Stoyanova- Scholz Infections in patients with rheumatoid arthritis treated with biologic agents Arthritis Rheum 52 2005 3403 3412
72. W.G. Dixon, K. Watson, M. Lunt, K.L. Hyrich, A.J. Silman, and D.P. Symmons Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid artritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register Arthritis Rheum 54 2006 2368 2376
73. J. Askling, C.M. Fored, L. Brandt, E. Baecklund, L. Bertilsson, and N. Feltelius Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists Ann Rheum Dis 66 2007 1339 1344